Trends in floating drug delivery systems

Journal of Scientific and Industrial Research

Volumn 65, Issue 1, 2006, Pages 11-21

  Patil, Jay M ^a   Hirlekar, R S ^a   Gide, P S ^a   Kadam, V J ^a  

^a BHARATI VIDYAPEETH S COLLEGE OF PHARMACY   (India)

Author keywords

Drug delivery systems; Floating drug delivery system (FDDS); Gastric residence times (GRT)

Indexed keywords

DRUG; SCIENCE AND TECHNOLOGY;

EID: 30644462951     PISSN: 00224456     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (79)

1. Hoffman A & Stepensky D, Pharmacodynamic aspects of modes of drug administration for optimization of drug therapy, Crit Rev Ther Drug Cartier Syst, 16 (1999) 571-639.
2. Hejazi R & Amiji M, Stomach-specific anti-H. pylori therapy. I: Preparation and characterization of tetracycline of a floating multiple-unit capsule, a high-density loaded chitosan microspheres, Int J Pharm, 235 (2002) 87-94.
3. Dave B S, Amin A F & Patel M, Gastroretentive drug delivery system of Ranitidine HCL formulation and in vitro evaluation, AAPS Pharm Sci Tech, 5 (2004) 1-10.
4. Sawicki W, Pharmacokinetics of verapamil and nor verapamil from controlled release floating pellets in humans, Eur J Pharm Biopharm, 53 (2002) 29-35.
5. Rubinstein A, Li V H K, Gruber P & Robinson J R, in Oral Sustained Release Formulations: Design and Evaluation, edited by A Yacobi & E Halperin-Walega (Pergamon Press, New York) 1988, 125-156.
6. Krogel I & Bodmeier R, Floating or pulsatile drug delivery systems based on coated effervescent cores, Int J Pharm, 187 (1999) 175-184.
7. Sheth P R & Tossounian J, The hydrodynamically balanced system (HBSe): A novel drug delivery system for oral use, Drug Dev Ind Pharm, 10 (1984) 313-339.
8. Ushimaru K, Nakamichi K & Saito H, Pharmaceutical preparations and a method of manufacturing them, US Pat 4, 702, 918, October 27, 1987.
9. Franz M R & Oth M P, Sustained release, bilayer buoyant dosage form, US Pat 5, 232, 704, August 3, 1993.
10. Desai S & Bolton S, A floating controlled-release drug delivery systems: in vitro-in vivo evaluation, Phann Res, 10 (1993) 1321-1325.
11. Bolton S & Desai S, Floating sustained release therapeutic compositions, US Pat 4, 814, 179, March 21, 1989.
12. Dennis P, Timmins K & Lee S, Buoyant controlled release powder formulation, US Pat 5, 169, 638, December 8, 1992.
13. Mitra S B, Sustained release oral medicinal delivery device, US Pat 4, 451, 260, May 29, 1984.
14. Thanoo B C, Sunny M C & Jayakrishnan A, Oral sustained release drug delivery systems using polycarbonate microspheres capable of floating on the gastric fluid, J Pharm Pharmacol, 45 (1993) 21-24.
15. Kawashima Y, Niwa T, Takeuchi H., Hino T & Ito Y, Preparation of multiple unit hollow microspheres (microballoons) with acrylic resin containing tranilast and their drug release characteristics (in vitro) and floating behavior (in vivo), J Control Release, 16 (1991) 279-290.
16. Kawashima Y, Niwa T, Takeuchi H, Hino T & Ito Y, Hollow microspheres for use as a floating controlled drug delivery system in the stomach, J Pharm Sci, 81 (1992) 135-140.
17. Harrigan R M, Drug delivery device for preventing contact of undissolved drug with the stomach lining, US Pat 4, 055, 178, October 25, 1977.
18. Whitehead L, Fell J & Collett J H, Relevant of a gastroretentive dosage form, Eur J Pharm Sci, 4 (Suppl) (1996) S182.
19. Krogel I & Bodmeier R, Development of a multifunctional matrix drug delivery system surrounded by an impermeable cylinder, J Control Release, 61 (1999) 43-50.
20. Streubel A, Siepmann J & Bodmeier R, Floating matrix tablets based on low density foam powder: Effects of formulation and processing parameters on drug release, Eur J Pharm Sci, 18 (2003) 37-45.
21. Jain S K & Agrawal G P, Floating Flap: A sustained release polymeric device for the delivery of Albendazole and closantel for veterinary use, Ind J Pharm Sci, 66 (2004) 63-68.
22. Heijazi R & Amiji M Chitosan based gastrointestinal delivery systems, J Control Release, 89 (2003) 151-165.
23. 1 induced apoptosis in rat liver, Int J Pharm, 260 (2003) 5-22.
24. Dennis A B, Farr S J, Kellaway I W, Taylor G & Davidson R, In vivo evaluation of rapid release and sustained release Gelucire capsule formulations, Int J Pharm, 65 (1990) 85-100.
25. Remunan C, Bretal M, Nunez A & Bila Jato J L, Accelerated stability of sustained release tablet prepared with Gelucire, Int J Pharm, 80 (1992) 151-159.
26. Saraiya D & Bolton D, The use of Percirol to prepare sustained release tablets of theophylline and quinidine gluconate, Drug Dev Ind Pharm, 6 (1990) 1963-1969.
27. Li S, Lin S, Chien Y W, Daggy B P & Mirchandani H L. Statistical optimization of gastric floating system for oral controlled delivery of calcium, AAPS Pharm Sci Tech, 2 (2001) 1:E1.
28. Kumar K, Shah M H, Ketkar A R, Kadam S S & Paradkar A. Effect of drug solubility and different excipients on floating behavior and release from glyceryl mono-oleate matrices, Int J Pharm, 272 (2004) 151-160.
29. Shimpi S, Chauhan B, Mahadik K R & Paradkar A, Preparation and evaluation of Diltiazem Hydrochloride Gelucire 43/01 floating granules prepared by Melt Granulation, AAPS Pharm Sci Tech, 5 (2004) 3:E1.
30. Kolter et al, Active ingredient containing floating forms comprising polyvinyl acetate and polyvinyl pyrrolidone, their use and production, US pat 6,635,279.
31. Chen et al, Gastric retention properties of superporous hydrogel composites, J Control Release, 64 (2001) 39-51.
32. Ritschel W A, Targeting in the gastrointestinal tract: new approaches, Methods Find Exp Clin Pharmacol, 13 (1991) 313-336.
33. Michaels A S, Bashwa J D & Zaffaroni A, Integrated device for administering beneficial drug at programmed rate, US Pat 3, 901, 232, August 26, 1975.
34. Michaels A S, Drug delivery device with self-actuated. Mechanism for retaining device in selected area, US Pat 3, 786, 813, January 22, 1974.
35. Hashim H & Li Wan Po A, Improving the release characteristics of water-soluble drugs from hydrophilic sustained release matrices by in situ gas-generation, Int J Pharm, 35 (1987) 201-206.
36. Ichikawa M, Watanabe S & Miyake Y, A new multiple-unit oral floating dosage systems. I: Preparation and in vitro evaluation of floating and sustained release characteristics, J Pharm Sci, 89 (1991) 1062-1066.
37. Ingani H M, Timmermans J & Moes A J, Conception and in vivo investigation of peroral sustained release floating dosage forms with enhanced gastrointestinal transit, Int J Pharm, 35 (1987) 157-164.
38. Inouye K, Machida Y, Sannan T & Nagai T, Buoyant sustained release tablets based on chitosan, Drug Des Del, 2 (1988) 165-175.
39. Ichikawa M, Watanabe S & Miyake Y, Granule remaining in stomach, US Pat 4, 844, 905, July 4, 1989.
40. Umamaheshwari R B, Jain S & Jain N K, A new approach in gastroretentive drug delivery system using cholestyramine, Drug Deliv, 10 (2003) 151-160.
41. Atyabi F, Sharma H L, Mohammad A H & Fell J T, In vivo evaluation of a novel gastric retentive formulation based on ion exchange resins, J Control Release, 42 (1996) 105-113.
42. Choi B Y, Park H J & Hwang S J, Preparation of alginate beads for floating drug delivery effects of carbon dioxide gas forming agents, Int J Pharm, 239 (2002) 81-91.
43. Paterson R S, O'mahony B, Eccleston G M, Stevens H N E, Foster J & Murray J G, An assessment of floating raft formation in man using magnetic resonance imaging, J Pharm Pharmacol, 8 (2000) S2 (suppl).
44. Oth M, Franz M, Timmermans J & Moes A, The bilayer floating capsule: a stomach-directed drug delivery system for misoprostol, Pharm Res, 9 (1992) 298-302.
45. Watanabe K, Machida Y. Takayama K, Iwata M & Nagai T, Preparation and evaluation of intragastric floating tablet having pH independent buoyancy and sustained release property, Arch Pract Pharm, 53 (1993) 1-7.
46. Rouge N, Buri P & Doelker E, Drug absorption sites in the gastrointestinal tract and dosage forms for site-specific delivery, Int J Pharm, 136 (1996) 117-139.
47. Wong P S L, Dong L C, Edgren D E, Theeuwes F,Gardner P I, Jao F & Wan J J, Prolonged release active agent dosage form adapted for gastric retention, US Pat 6120803, September 19, 2000.
48. El-Kamel A H, Sokar M S, Gamal S S A & Naggar V F, preparation and evaluation of ketoprofen floating oral delivery system, Int J Pharm, 220 (2001) 13-21.
49. Groning R, Berntgen M & Georgarakis M, Acyclovir serum concentrations following peroral administration of magnetic depot tablets and the influence of extra corporal magnet to control gastrointestinal transit, Eur J Pharm Biopharm, 46 (1996) 285-291.
50. Flashner-Barak M, Rosenberger V, Dahan M & Lerner Y. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates, US Pat 6476006, November 5, 2002.
51. Rouge N, Allemann E, Gex-Fabry M, Balant L, Cole E T, Buri P & Doelker E, Comparative phannacokinetic study of a floating multiple-unit capsule, a high-density multiple-unit capsule and an immediate-release tablet containing 25 mg atenolol, Pharm Acta Helv, 73 (1998) 81-87.
52. Nur A O & Zhang J S, Captopril floating and/or bioadhesive tablets: design and release kinetics, Drug Dev Ind Pharm, 26 (2000) 965-969.
53. Louie-Helm J, Fell R, Shell J N, Dye D, Levy G, Gorsline J, Mueller M, Dilger C & Berner B, Pharmacokinetics of ciprofloxacin gastric retentive tablets in healthy volunteers, Proc Int Symp Control Rel Bioact Mater, San Diego, 2001.
54. Klausner E A Lavy E, Stepensky D, Cserepes E, Barta M, Friedman M & Hoffman A, Furosemide pharmacokinetics and pharmacodynamics following gastroretentive dosage form administration to healthy volunteers, J Clin Pharmacol, 43 (2003) 711-720.
55. Eiamntrakarn S, Itoh Y, Kishimoto J, Yoshikawa Y, Shibata, Murakami M & Takada. K, Gastrointestinal mucoadhesive patch system (GI-MAPS) for oral administration of G-CSF, a model protein, Biomaterials, 23 (2002) 145-152.
56. Curatolo W J & Lo J, Gastric retention system for controlled drug release, US Pat 5443843, August 22, 1995.
57. Gibaly I E, Development and in vitro evaluation of novel floating chitosan microcapsules for oral use: comparison with nonfloating chitosan microspheres, Int J Pharm, 249 (1998) 55-62.
58. Gusler G, Gorsline J, Levy G, Zhang S Z, Weston I E & Berner D B, Pharmacokinetics of metformin gastric retentive tablets in healthy volunteers, J Clin Pharmacol, 41 (2001) 655-661.
59. Jao F, Edgren D E & Wong P S, Gastric retention dosage form having multiple layers, Int Application WO0038650, July 6, 2000.
60. Shalaby W S W, Blevins W E & Park K, In vitro and in vivo studies of enzyme-digestible hydrogels for oral drug delivery, J Control Release, 19 (1992) 131-144.
61. Chueh H R, Zia H, & Rhodes C T, Optimization of sotalol floating and bioadhesive extended release tablet formulations, Drug Dev Ind Pharm, 21 (1995) 1725-1747.
62. Sheth P R & Tossounian J L, Novel sustained release tablet formulations, US Pat 4,167,558, September 11, 1979.
63. Hilton A K & Deasy P B, In vitro and in vivo evaluation of an oral stained-release floating dosage form of amoxycillin trihydrate, Int J Pharm, 86 (1992) 79-88.
64. Jayanthi G, Jayaswal S B & Srivastava A K Formulation and evaluation of terfenadine microballoons for oral controlled release, Pharmazie, 50 (1995) 769-770.
65. Gu T H, Chen S X, Zhu J B, Song D J, Guo J Z & Hou H M, Pharmacokinetics and pharmacodynamics of diltiazem sustained floating tablets, Chung Kuo Yao Li Hsueh Pao, 13 (1992) 527-531.
66. Inouye K, Machida Y, Sannan T & Nagai T, Buoyant sustained release granules based on chitosan, Drug Des Del, 4 (1989) 55-67.
67. Chitnis V S, Malshe V S & Lalla J K, Bioadhesive polymers synthesis, evaluation and application in controlled release tablets, Drug Dev Ind Pharm, 17 (1991) 879-892.
68. Rouge N, Cole E T, Doelker E & Buri P, Buoyancy and drug release patterns of floating minitablets containing piretanide and atenolol as model drugs, Pharm Dev Technol, 3 (1998) 4033-4038.
69. Inouye K, Machida Y, Sannan T & Nagai T, Buoyant sustained release tablets based on chitosan, Drug Des Del, 2 (1988) 165-175.
70. Chen G L & Hao W H, In vitro performance of floating sustained-release capsule of verapamil, Drug Dev Ind, 24 (1998) 1067-1072.
71. Sheth P R & Tossounian J, The hydrodynamically balanced system (HBSe): a novel drug delivery system for oral use, Drug Dev Ind Pharm, 10 (1984) 313-339.
72. Gustafson J H, Weissman L, Weinfeld R E, Holazo A A, Khoo K C & Kaplan S A, Clinical bioavailability evaluation of a controlled release formulation of diazepam, J Pharmacokinet Biopharm, 9 (1981) 679-691.
73. Chauhan B, Shimpi S, Mahadik K R & Paradkar A, Preparation and evaluation of floating risedronate sodium Gelucire® 39/01 matrices, Acta Pharm, 54 (2004) 205-214.
74. Singh R N & Kim K H, Floating drug delivery systems: An approach to oral controlled drug delivery via gastric retention, J Control Release, 63 (2000) 235-259.
75. Burns S J, Corness D, Hay G, Higginbottom S, Whelan I, Attwood D & Barnwell S G, Development and validation of an in vitro dissolution method for a floating dosage form with biphasic release characteristics, Int J Pharm, 121 (1995) 37-44.
76. Gansbeke B V, Timmermans J, Schoutens A & Moes A J, Intragastric positioning of two concurrently ingested pharmaceutical matrix dosage forms, Nucl Med Biol, 18 (1991) 711-718.
77. Horton R E, Ross F G M & Darling GH, Determination of the emptying-time of the stomach by use of enteric-coated barium granules, Br Med J, 1 (1965) 1537-1538.
78. Hendee W R, in Texbook of Diagnosti Imaging II, vol 1, edited by C E Putman & C E Ravin (W B Saunder, Philadelphia) 1994, 1-6.
79. Steingotter A, Weishaupt D, KunzMader P, Legsfeld K, Thumshim H M, Boesinger P, Fried M & Schwizer W, Magnetic resonance imaging for the in vivo evaluation of gastric retentive tablets, Pharm Res, 20 (2003) 2001-2007.